Eli Lilly Company Insiders
LLY Stock | USD 731.33 5.02 0.69% |
Slightly above 64% of Eli Lilly's corporate insiders are selling. The analysis of insiders' sentiment of trading Eli Lilly and stock suggests that many insiders are alarmed at this time. Eli Lilly employs about 43 K people. The company is managed by 61 executives with a total tenure of roughly 487 years, averaging almost 7.0 years of service per executive, having 704.92 employees per reported executive.
John Lechleiter Chairman Chairman, CEO and Pres |
Alfonso Zulueta President Senior Vice President and President - Emerging Markets business |
Eli Lilly's Insider Buying Vs Selling
36
Selling | Buying |
Latest Trades
2024-02-08 | Josh Gottheimer | Disposed @ 735.56 | |||
2024-01-31 | Lilly Endowment Inc | Disposed 78573 @ 648.07 | View | ||
2024-01-29 | Lilly Endowment Inc | Disposed 54032 @ 645.07 | View | ||
2024-01-16 | Lilly Endowment Inc | Disposed 1180 @ 645.6 | View | ||
2024-01-11 | Lilly Endowment Inc | Disposed 12344 @ 634.13 | View | ||
2024-01-09 | Lilly Endowment Inc | Disposed 34538 @ 631.81 | View | ||
2024-01-04 | Lilly Endowment Inc | Disposed 14388 @ 630.28 | View | ||
2024-01-03 | Tommy Tuberville | Disposed @ 617.63 | |||
2023-12-28 | Jared Moskowitz | Acquired @ 581.28 | |||
2023-12-14 | Sheldon Whitehouse | Acquired @ 573.69 | |||
2023-12-04 | John R. Curtis | Disposed @ 585.56 | |||
2023-11-16 | Josh Gottheimer | Acquired @ 588.75 | |||
2023-11-13 | Josh Gottheimer | Acquired @ 613.17 | |||
2023-11-06 | Donald A Zakrowski | Disposed 670 @ 571.1 | View | ||
2023-10-24 | Greg Stanton | Disposed @ 592.43 | |||
2023-10-11 | Lilly Endowment Inc | Disposed 215000 @ 605.44 | View | ||
2023-10-03 | Markwayne Mullin | Acquired @ 525.1 | |||
2023-09-26 | Greg Stanton | Acquired @ 549.96 | |||
2023-09-21 | Josh Gottheimer | Acquired @ 550.13 |
Monitoring Eli Lilly's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Acquired vs Disposed
Filed vs Not Filed
Insider sentiment refers to the collective sentiment or feeling of Eli Lilly's insiders - typically its officers, directors, and beneficial owners holding more than a certain percentage of the company's stock - about the future prospects of Eli Lilly and. This sentiment is often gauged based on the trading activities of these insiders. If insiders are purchasing more shares of their own company, it may be interpreted as a bullish sentiment, indicating that they believe Eli Lilly's stock will rise in value. Conversely, if insiders are selling shares, it might be seen as bearish, suggesting they expect the stock price to drop.
Eli |
Eli Lilly's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Eli Lilly's future performance. Based on our forecasts, it is anticipated that Eli will maintain a workforce of slightly above 43000 employees by May 2024.Eli Lilly's latest congressional trading
Congressional trading in companies like Eli Lilly, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Eli Lilly by those in governmental positions are based on the same information available to the general public.
2024-02-08 | Representative Josh Gottheimer | Disposed Under $15K | Verify | ||
2023-12-14 | Senator Sheldon Whitehouse | Acquired Under $15K | Verify | ||
2023-12-04 | Representative John Curtis | Disposed Under $15K | Verify | ||
2023-10-24 | Representative Greg Stanton | Disposed Under $15K | Verify | ||
2023-03-07 | Representative Daniel Goldman | Acquired Under $15K | Verify | ||
2022-11-28 | Representative Van Taylor | Disposed $1,000,001 - $5,000,000 | Verify | ||
2022-08-04 | Representative Bob Gibbs | Disposed Under $15K | Verify | ||
2022-07-15 | Representative Kathy Manning | Acquired Under $15K | Verify | ||
2022-03-08 | Representative Dan Newhouse | Acquired Under $15K | Verify | ||
2022-01-14 | Senator Tommy Tuberville | Acquired $15K to $50K | Verify | ||
2021-03-05 | Representative Michael T. McCaul | Disposed $250K to $500K | Verify | ||
2021-02-05 | Representative Kurt Schrader | Acquired Under $15K | Verify | ||
2020-04-16 | Senator David A Perdue , Jr | Acquired Under $15K | Verify | ||
2020-04-16 | Senator David Perdue | Acquired Under $15K | Verify | ||
2020-04-07 | Senator Kelly Loeffler | Acquired Under $15K | Verify | ||
2020-03-26 | Representative Steve Cohen | Disposed Under $15K | Verify | ||
2020-02-20 | Representative Mikie Sherrill | Disposed Under $15K | Verify | ||
2019-10-17 | Representative Thomas Suozzi | Disposed Under $15K | Verify | ||
2019-02-28 | Representative Alan S. Lowenthal | Acquired Under $15K | Verify | ||
2018-08-30 | Representative Zoe Lofgren | Disposed Under $15K | Verify |
Eli Lilly Management Team Effectiveness
The company has Return on Asset of 0.1188 % which means that on every $100 spent on assets, it made $0.1188 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.4844 %, implying that it generated $0.4844 on every 100 dollars invested. Eli Lilly's management efficiency ratios could be used to measure how well Eli Lilly manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Eli Lilly's Return On Tangible Assets are fairly stable compared to the past year. Return On Assets is likely to rise to 0.12 in 2024, whereas Return On Capital Employed is likely to drop 0.25 in 2024. At this time, Eli Lilly's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 40.2 B in 2024, whereas Non Currrent Assets Other are likely to drop slightly above 2.9 B in 2024.Common Stock Shares Outstanding is likely to drop to about 868.4 M in 2024. Net Income Applicable To Common Shares is likely to drop to about 4 B in 2024
Eli Lilly Workforce Comparison
Eli Lilly and is currently regarded as number one stock in number of employees category among related companies. The total workforce of Health Care industry is now estimated at about 50,320. Eli Lilly totals roughly 43,000 in number of employees claiming about 85% of equities under Health Care industry.
Eli Lilly Profit Margins
The company has Net Profit Margin of 0.15 %, which implies that it may need a different competitive strategy as even a very small decline in it revenue may erase profits and result in a net loss. This is way below average. In the same way, it shows Net Operating Margin of 0.34 %, which entails that for every 100 dollars of revenue, it generated $0.34 of operating income.Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Gross Profit Margin | 0.62 | 0.8073 |
|
| |||||
Operating Profit Margin | 0.28 | 0.3026 |
|
| |||||
Pretax Profit Margin | 0.25 | 0.1921 |
|
|
Eli Lilly Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Eli Lilly insiders, such as employees or executives, is commonly permitted as long as it does not rely on Eli Lilly's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Eli Lilly insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2024-03-01 | 0.5 | 50 | 100 | 215,448 | 960,188 |
2023-12-01 | 2.8 | 28 | 10 | 8,444 | 237,639 |
2023-09-01 | 0.2 | 18 | 90 | 349.00 | 1,057,853 |
2023-06-01 | 0.25 | 20 | 80 | 6,738 | 1,534,042 |
2023-03-01 | 1.6571 | 58 | 35 | 305,462 | 568,377 |
2022-12-01 | 0.6739 | 31 | 46 | 29,999,033 | 826,106 |
2022-09-01 | 0.6818 | 15 | 22 | 1,145 | 389,429 |
2022-06-01 | 0.2432 | 18 | 74 | 8,156 | 2,004,859 |
2022-03-01 | 0.902 | 46 | 51 | 368,717 | 1,486,308 |
2021-12-01 | 0.7857 | 22 | 28 | 11,953 | 784,800 |
2021-09-01 | 0.2432 | 9 | 37 | 277.00 | 1,150,592 |
2021-06-01 | 0.3333 | 12 | 36 | 21,861 | 905,898 |
2021-03-01 | 1.1892 | 44 | 37 | 34,902,818 | 1,073,169 |
2020-12-01 | 3.2 | 16 | 5 | 27,737 | 11,429 |
2020-09-01 | 0.3125 | 5 | 16 | 8,750 | 474,970 |
2020-06-01 | 0.0638 | 3 | 47 | 38.00 | 1,771,775 |
2020-03-01 | 0.9189 | 34 | 37 | 41,403,910 | 1,495,503 |
2019-12-01 | 0.8966 | 26 | 29 | 32,949 | 2,069,427 |
2019-09-01 | 1.2727 | 14 | 11 | 3,637 | 266,426 |
2019-06-01 | 1.6667 | 15 | 9 | 15,221 | 67,112 |
2019-03-01 | 1.4737 | 56 | 38 | 584,626 | 1,405,426 |
2018-12-01 | 0.7097 | 22 | 31 | 31,101 | 1,454,683 |
2018-09-01 | 0.3824 | 13 | 34 | 9,148 | 2,659,746 |
2018-06-01 | 0.56 | 14 | 25 | 64,807 | 1,212,526 |
2018-03-01 | 1.6563 | 53 | 32 | 494,550 | 316,850 |
2017-12-01 | 1.375 | 22 | 16 | 77,327 | 507,830 |
2017-09-01 | 1.0 | 7 | 7 | 8,018 | 785,000 |
2017-06-01 | 0.6667 | 8 | 12 | 415,314 | 879,635 |
2017-03-01 | 1.25 | 30 | 24 | 668,132 | 1,084,680 |
2016-12-01 | 2.0 | 16 | 8 | 29,513 | 228,052 |
2016-09-01 | 0.8 | 8 | 10 | 15,136 | 897,358 |
2016-06-01 | 0.3077 | 4 | 13 | 1,339 | 1,207,680 |
2016-03-01 | 1.5 | 30 | 20 | 500,130 | 203,419 |
2015-12-01 | 0.5909 | 13 | 22 | 100,712 | 1,690,126 |
2015-06-01 | 0.15 | 3 | 20 | 127,108 | 1,686,579 |
2015-03-01 | 0.8485 | 28 | 33 | 688,717 | 847,772 |
2014-12-01 | 0.6364 | 14 | 22 | 175,038 | 1,635,403 |
2014-09-01 | 0.2727 | 6 | 22 | 60,347 | 1,246,453 |
2014-06-01 | 0.1176 | 2 | 17 | 17,157 | 2,082,530 |
2014-03-01 | 1.5789 | 30 | 19 | 863,010 | 326,988 |
2013-12-01 | 2.75 | 11 | 4 | 28,205 | 5,962 |
2013-06-01 | 0.2222 | 2 | 9 | 20,000 | 57,833 |
2013-03-01 | 1.2174 | 28 | 23 | 888,564 | 571,211 |
2012-12-01 | 1.375 | 11 | 8 | 40,268 | 45,414 |
2012-03-01 | 1.7059 | 29 | 17 | 971,937 | 668,281 |
2011-12-01 | 2.4 | 12 | 5 | 41,447 | 35,107 |
2011-09-01 | 1.6667 | 5 | 3 | 4,200 | 9,618 |
2011-06-01 | 0.5556 | 5 | 9 | 8,354 | 34,101 |
2011-03-01 | 0.8333 | 20 | 24 | 914,445 | 658,293 |
2010-12-01 | 3.5 | 7 | 2 | 29,309 | 2,489 |
2010-03-01 | 0.7037 | 19 | 27 | 889,577 | 357,814 |
2009-12-01 | 4.6667 | 14 | 3 | 34,207 | 2,673 |
2009-09-01 | 8.0 | 8 | 1 | 7,142 | 187.00 |
2009-06-01 | 0.75 | 3 | 4 | 657.00 | 30,463 |
2009-03-01 | 0.8462 | 11 | 13 | 296,407 | 196,494 |
2008-12-01 | 10.0 | 10 | 1 | 32,452 | 0.00 |
2008-09-01 | 0.0019 | 3 | 1604 | 466.00 | 1,835,000 |
2008-03-01 | 0.5556 | 15 | 27 | 259,272 | 231,713 |
2007-12-01 | 13.0 | 13 | 1 | 20,632 | 1,626 |
2007-09-01 | 0.0422 | 7 | 166 | 5,711 | 365,596 |
2007-06-01 | 0.0111 | 8 | 720 | 100,584 | 2,632,780 |
2007-03-01 | 0.6957 | 16 | 23 | 198,146 | 292,245 |
2006-12-01 | 0.0237 | 14 | 591 | 27,454 | 1,358,650 |
2006-09-01 | 0.0152 | 12 | 790 | 21,922 | 2,153,422 |
2006-06-01 | 0.0056 | 6 | 1068 | 705.00 | 2,987,068 |
2006-03-01 | 0.0734 | 24 | 327 | 608,381 | 1,324,359 |
2005-12-01 | 1.2667 | 19 | 15 | 128,874 | 263,933 |
2005-09-01 | 0.0147 | 16 | 1089 | 54,709 | 2,690,655 |
2005-06-01 | 0.0256 | 12 | 468 | 137,093 | 1,097,238 |
2005-03-01 | 1.2222 | 22 | 18 | 501,531 | 241,686 |
2004-12-01 | 4.6667 | 14 | 3 | 31,608 | 24,500 |
2004-09-01 | 0.0154 | 8 | 518 | 46,788 | 884,814 |
2004-06-01 | 0.0101 | 8 | 795 | 4,030 | 1,720,872 |
2004-03-01 | 0.1301 | 19 | 146 | 616,904 | 645,667 |
2003-12-01 | 0.1579 | 12 | 76 | 4,541 | 165,100 |
2003-09-01 | 0.005 | 6 | 1210 | 348.21 | 2,615,255 |
2003-06-01 | 0.5 | 1 | 2 | 1,000.00 | 1,863 |
Eli Lilly Notable Stakeholders
An Eli Lilly stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Eli Lilly often face trade-offs trying to please all of them. Eli Lilly's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Eli Lilly's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Jacob Naarden | Senior Vice President, Chief Executive Officer - Loxo Oncology at Lilly, President - Lilly Oncology | Profile | |
John Lechleiter | Chairman, CEO and Pres | Profile | |
Johna Norton | Senior Vice President - Global Quality | Profile | |
Alfonso Zulueta | Senior Vice President and President - Emerging Markets business | Profile | |
Anne White | Senior Vice President and Presidentident - Lilly Oncology | Profile | |
Melissa Barnes | Senior Vice President - Enterprise Risk Management and Chief Ethics and Compliance Officer | Profile | |
Patrik Jonsson | Senior Vice President, Chief Customer Officer, President - Lilly Immunology, Lilly USA | Profile | |
Enrique Conterno | Senior Vice President and President - Lilly Diabetes and President - Lilly USA | Profile | |
Myles ONeill | Senior Vice President and President - Manufacturing Operations | Profile | |
David Ricks | Senior Vice President and Presidentident - Lilly Bio-Medicines | Profile | |
Daniel Skovronsky | Senior Vice President, Chief Scientific and Medical Officer, President - Lilly Research Laboratories | Profile | |
Joshua Smiley | Chief Financial Officer, Senior Vice President | Profile | |
Anat Hakim | Senior Vice President, General Counsel, Secretary | Profile | |
Fionnuala Walsh | Senior Vice President - Global Quality | Profile | |
Anat Ashkenazi | Chief Financial Officer, Senior Vice President | Profile | |
Jeffrey Simmons | Senior Vice President and President - Elanco Animal Health | Profile | |
Leigh Pusey | Senior Vice President - Corporate Affairs and Communications | Profile | |
Darren Carroll | Senior Vice President - Corporate Business Development | Profile | |
Christi Shaw | Senior Vice President and President - Lilly Bio-Medicines | Profile | |
Barton Peterson | Senior Vice President - Corporate Affairs and Communications | Profile | |
Michael Harrington | Executive Vice President, General Counsel | Profile | |
Maria Crowe | President - Manufacturing Operations | Profile | |
Jan Lundberg | Executive VP of Science and Technology and President of Lilly Research Laboratories | Profile | |
Aarti Shah | Senior Vice President - Chief Information and Digital Officer | Profile | |
Susan Mahony | Senior Vice President and President - Lilly Oncology | Profile | |
Stephen Fry | Senior Vice President - Human Resources and Diversity | Profile | |
Derica Rice | CFO, Executive VP of Global Services, Member of Operations Committee and Member of Policy and Strategy Committee | Profile | |
Ralph Alvarez | Independent Director | Profile | |
Jamere Jackson | Independent Director | Profile | |
Juan Luciano | Lead Independent Director | Profile | |
Karen Walker | Independent Director | Profile | |
Raul Alvarez | Independent Director | Profile | |
Marschall Runge | Independent Director | Profile | |
Carolyn Bertozzi | Independent Director | Profile | |
Erik Fyrwald | Independent Director | Profile | |
Franklyn Prendergast | Independent Director | Profile | |
Ellen Marram | Lead Independent Director | Profile | |
Kathi Seifert | Independent Director | Profile | |
Gabrielle Sulzberger | Independent Director | Profile | |
Karen Horn | Independent Director | Profile | |
William Kaelin | Independent Director | Profile | |
David Hoover | Independent Director | Profile | |
Jackson Tai | Independent Director | Profile | |
Michael Eskew | Independent Director | Profile | |
Katherine Baicker | Independent Director | Profile | |
Bronwen Mantlo | Deputy VP | Profile | |
Anat JD | General VP | Profile | |
J Fyrwald | Independent Director | Profile | |
Mark MD | Senior Development | Profile | |
Ilya Yuffa | Senior Vice President and President of Lilly Bio-Medicines | Profile | |
Edgardo Hernandez | Senior Vice President and Presidentident - Manufacturing Operations | Profile | |
Donald Zakrowski | Senior Officer | Profile | |
David MD | Chief Officer | Profile | |
Eric Dozier | Executive Diversity | Profile | |
Alonzo Weems | Senior Vice President - Enterprise Risk Management, Chief Ethics and Compliance Officer | Profile | |
Jim Greffet | Head Strategy | Profile | |
Kimberly Johnson | Independent Director | Profile | |
Diogo Rau | Senior Vice President Chief Information and Digital Officer | Profile | |
Martin MIBS | VP Projects | Profile | |
Michael Mason | Senior Vice President and President Lilly Diabetes | Profile | |
Winselow Tucker | Senior Loxo | Profile |
About Eli Lilly Management Performance
The success or failure of an entity such as Eli Lilly often depends on how effective the management is. Eli Lilly management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Eli management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Eli management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | 0.10 | 0.14 | |
Return On Capital Employed | 0.28 | 0.25 | |
Return On Assets | 0.08 | 0.12 | |
Return On Equity | 0.49 | 0.26 |
The data published in Eli Lilly's official financial statements usually reflect Eli Lilly's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Eli Lilly. For example, before you start analyzing numbers published by Eli accountants, it's critical to develop an understanding of what Eli Lilly's liquidity, profitability, and earnings quality are in the context of the Pharmaceuticals space in which it operates.
Please note, the presentation of Eli Lilly's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Eli Lilly's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Eli Lilly's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Eli Lilly and. Please utilize our Beneish M Score to check the likelihood of Eli Lilly's management manipulating its earnings.
Eli Lilly Workforce Analysis
Traditionally, organizations such as Eli Lilly use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Eli Lilly within its industry.Eli Lilly Manpower Efficiency
Return on Eli Lilly Manpower
Revenue Per Employee | 793.6K | |
Revenue Per Executive | 559.4M | |
Net Income Per Employee | 121.9K | |
Net Income Per Executive | 85.9M |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Eli Lilly and. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for Eli Stock analysis
When running Eli Lilly's price analysis, check to measure Eli Lilly's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eli Lilly is operating at the current time. Most of Eli Lilly's value examination focuses on studying past and present price action to predict the probability of Eli Lilly's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eli Lilly's price. Additionally, you may evaluate how the addition of Eli Lilly to your portfolios can decrease your overall portfolio volatility.
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |
Is Eli Lilly's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eli Lilly. If investors know Eli will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eli Lilly listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.13 | Dividend Share 4.52 | Earnings Share 5.78 | Revenue Per Share 37.908 | Quarterly Revenue Growth 0.281 |
The market value of Eli Lilly is measured differently than its book value, which is the value of Eli that is recorded on the company's balance sheet. Investors also form their own opinion of Eli Lilly's value that differs from its market value or its book value, called intrinsic value, which is Eli Lilly's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eli Lilly's market value can be influenced by many factors that don't directly affect Eli Lilly's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eli Lilly's value and its price as these two are different measures arrived at by different means. Investors typically determine if Eli Lilly is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eli Lilly's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.